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discovery?
Jeremy I. Ramsden,a Sebastian C. Cosgrove *bc and Nicholas J. Turner *a
The use of biocatalysts for fragment-based drug discovery has yet to be fully investigated, despite the
promise enzymes hold for the synthesis of poly-functional, non-protected small molecules. Here we
analyze products of the biocatalysis literature to demonstrate the potential for not only fragment
generation, but also the enzyme-mediated elaboration of these fragments. Our analysis demonstrates
that biocatalytic products can readily populate 3D chemical space, offering diverse catalytic approaches
to help generate new, bioactive molecules.Introduction
Synthetic pharmaceuticals are dominated by sp2-rich mole-
cules, and a small subset of functionalities and backbone
structures.1–3 This has been attributed to the available meth-
odologies, with transition-metal catalysed cross-coupling reac-
tions featuring strongly in the way that compounds are made.4
In particular, the discovery of Pd-catalysed methods in the late
1970s, namely the Suzuki, Negishi, Stille and Heck reactions,eremy Ramsden obtained an
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12the further development of them and other reactions such as
the Buchwald–Hartwig reaction, and additionally amide bond
formation, has delivered a rich toolbox of sp2 cross-coupling
reactions,5,6 and consequently sp2-rich products. Despite the
consistent, and successful, synthesis of generally 2D molecules
it is well-documented that sp3-rich molecules have a higher
success rate as drug candidates.7,8 Therefore, new methodolo-
gies that produce diverse sets of 3D molecules are essential in
identifying new molecular entities.9
In the late 1990s, Lipinski devised the ‘rule of 5’ (Ro5), a set
of criteria that successful small molecule orally available drug
compounds oen adhere to (Fig. 1).10 It has been noted that
molecules at the limit of the Ro5 space are not always ideal drug
candidates, and screening libraries generated by high-
throughput screening (HTS) in the 1990s were not structurally
diverse.11 Diversity-oriented synthesis (DOS) was developed to
focus on creating structural diversity in compound libraries inSebastian Cosgrove was awar-
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Fig. 1 Areas of chemical space targeted by different synthetic
approaches. Adapted from Nadin et al.17
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View Article Onlineorder to avoid narrow biological activity.12–14 DOS involves
generating libraries with variation in structure and functionality
from simple starting materials via complexity incorporating
reactions such as cycloadditions.15 Some DOS approaches have
been used to increase the fraction of sp3 hybridization (Fsp3)
and generate natural product-like screening sets.16 But as with
HTS, DOS libraries have been criticized for not being ‘lead-like’,
that is too large and lipophilic.17 The notion of lead-oriented
synthesis (LOS) was developed to focus on smaller molecules
in lead-like libraries.17 LOS is achieved through the application
of synthetic methods that deliver libraries with more desirable
molecular properties. These libraries can then be further
manipulated to afford the diverse substrate sets which have
‘ideal’ physicochemical properties that tend towards theNick Turner obtained his DPhil in
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(www.coebio3.org) and a co-director of SYNBIOCHEM, the BBSRC
Synthetic Biology Research Centre. He is also a co-founder of
Ingenza (www.ingenza.com). His research interests are in the area
of biocatalysis with particular emphasis on the discovery and
development of novel enzyme catalysed reactions for applications in
organic synthesis. His group is also interested in the application of
directed evolution technologies for the development of biocatalysts
with tailored functions.
This journal is © The Royal Society of Chemistry 2020Lipinski space. Libraries of lead-like compounds with the
desired properties have been generated by LOS, however this
recent development has yet to yield clinical candidates.18,19
Fragment-based drug discovery (FBDD) was a term rst used
around 20 years ago, and has become a signicant part of many
drug discovery programs since.20 It focuses on creating smaller
(<20 heavy atoms (not H)), diverse sets of simple molecules
which have weak interactions with targets of interest that more
likely adhere to a rule of three (Ro3: MW <300 Da, <3 rotatable
bonds, cLogP <3).21,22 These weak interactions are characterized
through biophysical methods (NMR, X-ray crystallography) and
this informs the synthetic evolution of the fragment to design
the nal compound.23 The success of FBDD over the last two
decades is highlighted by the number of candidates that have
reached clinical trials, and even full approval.20
A recent essay by Murray and Rees discussed the opportu-
nities and challenges that were presented to synthetic chemists
to help with the generation of suitable fragments for FBDD.24
The essay stated two requirements of organic synthesis for
FBDD:
1. The design and synthesis of new fragments: there is a need
for more unique fragments to complement those that are
already available.
2. Elaboration of weakly binding fragments to nM leads:
a toolbox of synthetic methods should be available to elaborate
the fragments upon biological characterization.
An additional key desire was for ‘methodology that works in
the presence of polar groups and permits functionalization via
multiple growth positions’.24 In addition, Erlanson et al. also
highlighted that over the next 20 years ‘The content of fragment
libraries [may be] better satised by more-3D compounds’.20 The
requirement for this type of methodology offers a prime
opportunity for biocatalysis.
Biocatalysis
Biocatalysts are naturally occurring catalysts that operate with
high selectivity.25 Their inherently selective nature makes
enzymes perfect candidates for fragment generation, delivering
small, poly-functional molecules without the need for
protecting-group chemistry. The number of available bio-
catalysts has been signicantly expanded by the advent of
directed evolution in the early 1990s.26 Through protein engi-
neering and directed evolution, chemists can now improve
enzymes and change their activity, delivering biocatalysts that
are not only process-suitable, but also with non-natural
substrate tolerance. The chemistry of engineered enzymes
now includes C–H hydroxylation,27 amine oxidation,28 sulde
oxidation,29 conjugate reduction,30 and sp2-halogenation,31 with
most proceeding with perfect selectivity. This ever-increasing
range of reactions underlines the role that biocatalysis could
play in the discovery of new biologically active molecules.
There are several reports of enzymes being engineered to
address issues in pharmaceutical manufacturing. A landmark
example was the directed evolution of a transaminase to replace
a Rh-catalysed high-pressure hydrogenation.32 The resulting
biocatalyst displayed improvements of 13% increase in overallChem. Sci., 2020, 11, 11104–11112 | 11105
Fig. 2 Two molecules with molecular weight and predicted logP
values. alogP values calculated at virtual computational chemistry
laboratory.36
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View Article Onlineyield, 53% increase in productivity and a 19% reduction in
waste produced. Whilst this remarkable process improvement
underlined the potential of enzymes for synthetic chemistry,
biocatalysis has still yet to see signicant application in early
stage drug discovery. This is despite the benets that bio-
catalysts can impart, namely functionalized, non-protected
aliphatic molecules, that have the potential to provide ideal
starting points for drug discovery.33 A recent article from the
Arnold group explored the use of engineered P450 enzymes
being used in concert with a Suzuki cross coupling reaction to
generate a small library (only four compounds) of cyclopropane
derivatives in the context of DOS.34
One example, from the labs of Merck, was a transamination
that was used to cyclise a prochiral diester compound to
produce a chiral lactam intermediate, used for the synthesis of
an API in insomnia treatment (Scheme 1).35
A global or partial reduction could lead to the fragments 1
and 2, which with careful selection of biocatalyst could also
generate either enantiomer alpha to nitrogen and therefore
deliver diastereomeric control (Fig. 2).
Both molecules contain functional handles for further
manipulation, as well as binding functions for activity. They
have molecular weights under 200 and predicted logP below 0.5.
They also contain multiple C–H bonds with different vectors for
growth, so with C–H functionalization one could envisage a host
of derivatives that could be synthesized.
Below, we discuss the implications of using biocatalysis for
fragment generation, and how it could also play a role in the
further functionalization and elaboration of these fragments to
for FBDD. Using the open-source computational tool LLAMA
(Lead-Likeness and Molecular Analysis)37 we assessed the three-
dimensionality of biocatalysis products with fragment-like
properties, and simulated their elaboration to generate plots
detailing where they and their potential derivatives sit within
chemical space. LLAMA is capable of assessing candidate
molecules as “scaffolds” to be decorated through the simulation
of reactions common to the medicinal chemist's toolbox,
allowing for evaluation of the lead-likeness of molecules
alongside principle moment of inertia (PMI). It was developed
with the aim of aiding lead-oriented synthesis, not FBDD,
however we re-tasked to the tool to the generation of virtual
libraries due to the ease with which it generates predicted
molecular properties and virtual libraries of decorated
compounds. PMI has been used in a crude way to describeScheme 1 Merck transaminase process for lactam intermediate
synthesis.
11106 | Chem. Sci., 2020, 11, 11104–11112molecular geometry and shape, and is discussed in more detail
elsewhere.38 We aimed to cover the breadth of the biocatalytic
toolbox, with areas such as lone enzyme, biocatalytic cascade
and chemoenzymatic synthesis considered through literature
highlights. The potential impact of directed evolution on frag-
ment generation, a technology which has hugely advanced the
process application of biocatalysts, is also discussed as recent
applications of this technique have tooled enzymes towards
chemistry not only novel to biocatalysis, but wider synthesis.Biocatalysis for fragment synthesis
Lone-enzyme synthesis of fragment-like molecules
While currently underutilized, the ability of biocatalysis to
generate a range of complex structures from simple precursors
asymmetrically makes it an ideal technology for fragment-like
generation. Advantages over chemocatalysts such as chemo-
selectivity allow for retrosynthetic disconnections not possible
with traditional synthesis.39 In the example from O'Reilly and
co-workers (Scheme 2), both transaminase (TA) and alcohol
dehydrogenase (ADH) enzymes are applied for selective trans-
formation of a ketone, which may then be followed by an aza/
oxo-Michael epimerization cascade to generate functionalized
fragments carrying two stereocenters from simple starting
materials.40,41
In the rst of these two manuscripts, the technique is
demonstrated with the stereocomplementary and commercially
available TA enzymes “ATA-117” and “ATA-113”.40 The excep-
tional selectivity of these enzymes allows for a retrosynthetic
Michael disconnection in which amination exclusively takes
place at the ketone carbonyl, and also avoids the amination of
the product ketone. This transformation also proceeds entirely
stereoselectively, with an ee of >99%, which directs the
proceeding epimerization and retains the asymmetry. The
authors demonstrate that through the choice of enzyme, either
enantiomer of product may be accessed with absolute selec-
tivity. While many chemocatalytic methodologies may deliver
enantiomerically enriched products, the unparalleled stereo-
selectivity that results from the environment of an enzyme
active site presents a huge advantage to fragment generation in
which architectures are constructed to probe an asymmetric
environment and therefore require stereopurity for true evalu-
ation. This methodology has recently seen expansion to alkyne
equivalents, generating exo-cyclic enamines.42
In the follow-up manuscript to this work, O'Reilly and co-
workers again demonstrate how enzyme selectivity may beThis journal is © The Royal Society of Chemistry 2020
Scheme 2 Biocatalytic cascade for generation of N- and O-hetero-
cycles using u-TA and ADH. Virtual plots generated using LLAMA
software.37
Scheme 3 IRED reduction/lithiation chemoenzymatic synthesis of
2,2-disubstituted azepane derivatives.
Perspective Chemical Science
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View Article Onlineexploited to perform this challenging retrosynthetic discon-
nection through the use of an ADH to deliver a range of tetra-
hydropyrans and tetrahydrofurans, moieties that are both
challenging to incorporate into synthesis and readily present in
bioactive molecules.41 Analysis of the products described across
the two manuscripts resulting from this biocatalytic method-
ology reveals that the heterocycles obtained present an oppor-
tunity to cover a wide region of chemical space. Example
products are within the parameters of the Ro3 and may be
functionalised along multiple vectors to yield diverse frag-
ments. Reduction of the carbonyls in the nal products could be
easily achieved biocatalytically or chemically, or hydrolysis of
the ester to produce the acid, thus removing the undesirable
functionality and still producing fragments in minimum
synthetic operations.
With the biocatalysts from this work having been sourced
commercially and applied on a preparative scale, this method-
ology highlights a prime example of the opportunity that bio-
catalysis offers to generate a diverse library of asymmetric sp3-
rich fragments from simple precursors (Scheme 2).This journal is © The Royal Society of Chemistry 2020Whilst the excellent selectivity of biocatalysis is indicative of
the power of this technology for controlled building into novel
chemical space, the toolbox remains limited to a basic set of
reactions when compared to those achievable through the use
of wider synthetic methods. To combat this, a strategy of che-
moenzymatic synthesis may be explored in which an enzyme
may select initial stereochemistry before products that would be
inaccessible using known biocatalytic techniques are synthe-
sized by methods that retain conguration.Chemoenzymatic synthesis of azepanes
The power of this approach to access challenging architectures
has been demonstrated by collaboration between the groups of
Turner & Clayden (Scheme 3).43 Amine oxidases and imine
reductases (IREDs) are well established enzymes for the chiral
resolution of saturated amine heterocycles, with certain
members of the latter family demonstrating a further ability toChem. Sci., 2020, 11, 11104–11112 | 11107
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View Article Onlinecatalyse reductive amination.44,45 This gives rise to biocatalytic
strategies for the synthesis of asymmetric azepanes, a biologi-
cally relevant yet underrepresented class of heterocycle.
Despite enantiocomplementary methods that proceed with
full selectivity, the reaction itself is a simple reduction that may
only generate products with a singular substitution at the
a carbon.
To access 2,2-disubstituted products the authors envisaged
a strategy of conversion to the corresponding N0-arylated urea
compounds followed by a lithium-mediated transfer of said aryl
substituent to the 2-position of the azepane and nally,
deprotection. Using this methodology a large product scope of
2,2-diarylated azepane scaffolds is generated by the authors
with medicinal relevance speculated. Analysis of these products
reveals a library of compounds that heavily inhabit “sphere-
like” chemical space. As molecules of this shape are the most
underexplored in FBDD, a strong potential for novel bioactivity
is implied. However, the products are limited in fragment-like
characteristics due to the lipophilicity of the diarylated prod-
ucts that lack functional handles. For this methodology to nd
application in medicinal chemistry, functional limitations must
be understood, and expansion should be sought to incorporate
further heteroatoms into both saturated and aromatic rings.
With the timescale pressures brought on by the economic
requirements of a pharmaceutical campaign, the need to opti-
mize both concurrent bio and chemocatalytic steps presents
a serious challenge. This underlines a requirement for the
development of more facile biocatalytic methodology to facili-
tate its adaptation in medicinal chemistry.Engineered metalloenzyme cyclopropanation
While difficulties in the optimization of chemoenzymatic
synthesis may limit its application, directed evolution allows for
an alternative approach to expanding the biocatalytic toolbox
beyond the scope of nature. As a technique, directed evolution
has been paramount in the success of biocatalytic process
chemistry with virtually all commercially applied enzymes
having been subjected to rounds of optimization. Whilst the
technique is typically considered as a method of improving
enzyme stability and substrate scope, it is increasingly being
applied by researchers to develop enzymes capable of per-
forming new transformations, oen not only novel to bio-
catalysis but synthesis as a whole. This was demonstrated to
great effect by Fasan and co-workers (Scheme 4) in the devel-
opment of an engineered biocatalyst from sperm whale
myoglobin capable of catalysing intramolecular cyclo-
propanation.46 Whilst this transformation has been demon-
strated by chemocatalytic methods, performing this complex
rearrangement within the connes of an enzyme active site
presents a unique challenge. However, through separate
directed evolution campaigns a toolbox of stereo-
complementary carbene transferases were created from this
oxygen storage protein. Remarkably, one (1R,5S,6S)-selective
variant was noted to reach 74% conversion to product within 15
minutes, with an enantiopurity of 99% when applied as a whole
cell biocatalyst. The ability of this catalyst to generate 3 chiral11108 | Chem. Sci., 2020, 11, 11104–11112centers from symmetrical starting materials with complete
stereocontrol highlights a huge potential for this biocatalyst in
providing fragment architectures. Furthermore, the
outstanding reaction rates provided by the closed active site and
the ease of accessing the catalyst through simply culturing E.
coli demonstrates the strong economic potential of introducing
biocatalysis to medicinal chemistry. While analysis reveals
potential to build into three-dimensional space, many
compounds generated from this product scope tended towards
atness on the PMI plot. This is likely related to the limitations
of LLAMA as soware, which is unable to cleave the initially
formed lactone or add to resulting functionalities. Despite this,
these unique scaffolds all display fragment-like properties.
Through further manipulation of the products shown, more
highly saturated fragments may be envisaged, through bio-
catalytic means or otherwise. In addition to the products shown
there, the Fasan group has extended the scope of the method-
ology to include fused cyclopropyl-benzofurans and lactams.47,48
The diverse nature of the products generated from these studies
highlight the direction that biocatalysis will take in the coming
years, producing scaffolds with increasing complexity through
less synthetic steps than is possible with other methods.Biocatalysis for fragment elaboration
As mentioned earlier, as well as fragment synthesis, another
important role for chemistry in FBDD is to be able to provide
methods for further functionalization of fragments.24 It is clear,
especially given the pace of growth of C–H activation method-
ology and photoredox catalysis for example,49,50 that many
transformations could be applied to the fragments shown
above. Indeed, C–H functionalization methodology as a tool for
direct elaboration of hits has been discussed and reported
recently.51 There is further potential for biocatalysis here as well,
with functionalization of inert C–H bonds attainable with
several routinely used enzymes.Engineered P450s
The cytochrome P450 enzyme class is well known for its
importance in metabolism, being used to identify potential
metabolites of drug candidates.52 In biocatalysis, further
application has been demonstrated in the mediation of
synthetic transformations.53,54 Despite being widely and well
known as C–H hydroxylation catalysts, recent engineering
efforts from several groups, but pioneered by the Arnold group,
have expanded the scope of the P450 toolbox.55
Arnold and co-workers found that a single mutation of the
P450 active site could alter the specicity of P450s, shiing
a signature UV-Vis peak for the CO-bound complex from 450 to
411 nm, and dubbing this new, engineered class of biocatalysts
the P411.56 Importantly, this new enzyme had a higher affinity
for the transfer of complexed carbenes as opposed to oxygen,
generating an engineered biocatalyst capable of mediating the
cyclopropanation of alkenes (similar to that discussed in
Scheme 4). This has since been expanded to encompass func-
tionalization of C–H bonds with a myriad of nucleophilicThis journal is © The Royal Society of Chemistry 2020
Scheme 4 Intramolecular cyclopropanation catalysed by myoglobin and coupled transformation of product.
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View Article Onlinepartners for formal C–H amination (A),57 Si–H insertion (B),58
and C–C bond formation (C, Scheme 5).59
The signicance of the P411 toolbox, as well as other similar
engineered heme enzymes,60 is that it can be readily expanded
through protein engineering to meet to the challenges set by
chemists. Furthermore, the freedom to operate in the presence
of polar functionality with perfect chemoselectivity is key to
solving the problems presented to chemists in fragment
elaboration.20,24Halogenases
Another class of enzyme key to elaboration success are the
halogenases.31 Halogenase biocatalysts transform inert C–H
bonds, primarily sp2, to an organohalide bond, proceeding
under ambient conditions using inorganic halide sources.
According to Roughley and Jordan's analysis, 20% of medicinal
chemistry reactions involve the use, or synthesis of organo-
halides, underlining the importance of methods for their
production.5 Therefore, the ability to perform this with enzymes
presents an opportunity to overcome a key limitation of FBDD:
the selective functionalization of identied fragments allows forScheme 5 C–H activation chemistry attainable with engineered P411
biocatalysts.
This journal is © The Royal Society of Chemistry 2020new strategies for elaboration that do not disrupt the binding
motif.
Several reports have detailed two-step procedures whereby in
situ halogenation is followed by functionalization of the acti-
vated bond. One example from the Lewis group showed
bromination of several indole derivatives, which was coupled to
Pd-catalysed transformations of the C–Br bond.61 It was ach-
ieved with work-up and then exposure of the crude biotrans-
formation procedure to the Pd-catalyst preparation. The
Mickleeld and Greaney labs overcame the incompatibility
issues through the use of a siloxane membrane, but importantly
two of the halogenases used permitted functionalization of
indole skeletons at the 5- and 6- positions, transformations
which are challenging for traditional synthetic catalysts
(Scheme 6).62
These substrates were all subsequently converted to the
respective arylated derivatives in one-pot, demonstrating the
applicability of the reported method.62 Importantly, it demon-
strates that growth of these fragments can be achieved into
multiple vectors without the need for protection of the parent
scaffold (free N–H/O–H/CO2H), and without interrupting the
binding modes of the molecules. Further work is required toScheme 6 Different halogenases permitting the selective bromination
of non-protected indole derivatives.
Chem. Sci., 2020, 11, 11104–11112 | 11109
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View Article Onlinediscover new halogenase enzymes to expand the substrate
scope. An elegant example from Goss and co-workers recently
revealed the rst natural iodinase, which had a broad substrate
scope towards the iodination of (hetero)aromatics.63 A genome
mining approach to biocatalyst discovery uncovered new
sequences that were distinct from many of the reported halo-
genases to date. This approach, combined with protein engi-
neering, could open up the application of halogenases and
make them essential tools for late-stage functionalization.Future of biocatalysis for FBDD
Protein discovery and engineering. Biocatalysis could clearly
play a role in the future of fragment generation and elaboration,
addressing two of the main challenges set to synthetic chemists
by medicinal chemists.20,24 There are still many areas in which
biocatalysis must improve to fully realise its potential, not only
in FBDD but wider synthesis.
The scope of non-natural substrates must be signicantly
increased to allow off-the-shelf biocatalyst application. Genome
mining approaches, such as that from the Goss group for
iodinase discovery,63 will certainly aid this, as uncovering new
sequences and proteins will uncover many undiscovered
‘natural’ chemistries. Additionally, expansion of the genetic
code to incorporate non-canonical amino acids can help
increase the chemistry that enzymes can do. A recent study by
Green and co-workers showed that incorporation of non-
canonical amino acid N-methylhistidine could accelerate the
rate of reaction of an articial hydrolytic enzyme (BH32), with
the nal mutant described in the study showing >9000 fold
improvement in activity versus N-methylhistidine in solution.64
This remarkable study shows what computational power and
HTS can do for the design of new biocatalysts.
Concomitantly to new enzyme discovery and design, there
needs to be comprehensive protein engineering campaigns to
further improve the stability and activity of novel biocatalysts.
Being able to easily apply them under industry-ready conditions
is essential to their combination with synthetic catalysts in
other applications.
Reaction engineering. Alongside protein engineering, reac-
tion engineering and process optimization solutions can also
change the way that biocatalysts are applied in the synthesis of
small molecules. Flow chemistry has emerged as an important
tool for organic synthesis in the past 20 years,65 and this has
recently become more prominent in biocatalysis as well.66,67 The
use of ow chemistry for biocatalysis continues to offer solu-
tions to problems that have proven long-standing and hard to
overcome, such as enzyme stability with immobilization,68
improving the kinetics of an enzymatic reaction by novel reactor
designs,69 and the easier integration of organic solvents.70 Other
technological solutions, including the use of non-aqueous
medias such as deep eutectic solvents (DESs),71 or membrane
separation for reaction compartmentalization,72 provide
a glimpse as to some of the potential ways biocatalysts could be
applied to circumvent issues with their application.
Importantly, the use of new technologies, such as compart-
mentalization or ow chemistry, will allow greater ease of11110 | Chem. Sci., 2020, 11, 11104–11112integration with more traditional synthetic methods. This
synergy between traditional and biocatalytic techniques, which
is already well documented,73 will streamline application of
biocatalysis in synthetic routes.Conclusions
Biocatalysis continues to evolve at a fast pace and as a conse-
quence the way we can use it, and envisage using it, is changing
rapidly. Already established as a key tool in process develop-
ment in the pharmaceutical industry, the diversity of new
chemistry that can now be performed with enzymes presents an
opportunity for increased application in early-stage fragment-
based drug discovery programs. The scope of the biocatalytic
toolbox is ever expanding, and with new technological solutions
being presented with equal pace, the opportunity for integra-
tion into fragment generation programs is greater than ever.Conflicts of interest
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Rev. Drug Discovery, 2018, 17, 709–727.
5 S. D. Roughley and A. M. Jordan, J. Med. Chem., 2011, 54,
3451–3479.
6 D. G. Brown and J. Boström, J. Med. Chem., 2016, 59, 4443–
4458.
7 F. Lovering, J. Bikker and C. Humblet, J. Med. Chem., 2009,
52, 6752–6756.
8 A. Karawajczyk, F. Giordanetto, J. Benningshof, D. Hamza,
T. Kalliokoski, K. Pouwer, R. Morgentin, A. Nelson,
G. Müller, A. Piechot and D. Tzalis, Drug Discovery Today,
2015, 20, 1310–1316.
9 D. J. Foley, A. Nelson and S. P. Marsden, Angew. Chem., Int.
Ed., 2016, 55, 13650–13657.
10 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney,
Adv. Drug Delivery Rev., 1997, 23, 3–25.This journal is © The Royal Society of Chemistry 2020
Perspective Chemical Science
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 0
7 
O
ct
ob
er
 2
02
0.
 D
ow
nl
oa
de
d 
on
 1
1/
18
/2
02
0 
12
:2
8:
09
 P
M
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
L
ic
en
ce
.
View Article Online11 O. O. Grygorenko, D. M. Volochnyuk, S. V. Ryabukhin and
D. B. Judd, Chem. – Eur. J., 2019, 26, 1196–1237.
12 S. L. Schreiber, Science, 2000, 287, 1964–1969.
13 W. R. J. D. Galloway, A. Isidro-Llobet and D. R. Spring, Nat.
Commun., 2010, 1, 1–13.
14 A. Trabocchi, Diversity-Oriented Synthesis: Basics and
Applications in Organic Synthesis, Drug Discovery, and
Chemical Biology, John Wiley & Sons Ltd, New Jersey, 2013.
15 C. J. Gerry and S. L. Schreiber, Curr. Opin. Chem. Biol., 2020,
56, 1–9.
16 D. Morton, S. Leach, C. Cordier, S. Warriner and A. Nelson,
Angew. Chem., Int. Ed., 2009, 48, 104–109.
17 A. Nadin, C. Hattotuwagama and I. Churcher, Angew. Chem.,
Int. Ed., 2012, 51, 1114–1122.
18 R. G. Doveston, P. Tosatti, M. Dow, D. J. Foley, H. Y. Li,
A. J. Campbell, D. House, I. Churcher, S. P. Marsden and
A. Nelson, Org. Biomol. Chem., 2015, 13, 859–865.
19 D. J. Foley, R. G. Doveston, I. Churcher, A. Nelson and
S. P. Marsden, Chem. Commun., 2015, 51, 11174–11177.
20 D. A. Erlanson, S. W. Fesik, R. E. Hubbard, W. Jahnke and
H. Jhoti, Nat. Rev. Drug Discovery, 2016, 15, 605–619.
21 M. Congreve, R. Carr, C. Murray and H. Jhoti, Drug Discovery
Today, 2003, 8, 876–877.
22 H. Jhoti, G. Williams, D. C. Rees and C. W. Murray, Nat. Rev.
Drug Discovery, 2013, 12, 644.
23 D. A. Erlanson, B. J. Davis and W. Jahnke, Cell Chem. Biol.,
2019, 26, 9–15.
24 C. W. Murray and D. C. Rees, Angew. Chem., Int. Ed., 2016, 55,
488–492.
25 R. A. Sheldon, D. Brady and M. L. Bode, Chem. Sci., 2020, 11,
2587–2605.
26 F. H. Arnold, Angew. Chem., Int. Ed., 2018, 57, 4143–4148.
27 R. Bernhardt and V. B. Urlacher, Appl. Microbiol. Biotechnol.,
2014, 98, 6185–6203.
28 N. J. Turner, Chem. Rev., 2011, 111, 4073–4087.
29 Y. K. Bong, S. Song, J. Nazor, M. Vogel, M. Widegren,
D. Smith, S. J. Collier, R. Wilson, S. M. Palanivel,
K. Narayanaswamy, B. Mijts, M. D. Clay, R. Fong,
J. Colbeck, A. Appaswami, S. Muley, J. Zhu, X. Zhang,
J. Liang and D. Entwistle, J. Org. Chem., 2018, 83, 7453–7458.
30 H. S. Toogood and N. S. Scrutton, ACS Catal., 2018, 8, 3532–
3549.
31 J. Latham, E. Brandenburger, S. A. Shepherd, B. R. K. Menon
and J. Mickleeld, Chem. Rev., 2018, 118, 232–269.
32 C. K. Savile, J. M. Janey, E. C. Mundorff, J. C. Moore, S. Tam,
W. R. Jarvis, J. C. Colbeck, A. Krebber, F. J. Fleitz, J. Brands,
P. N. Devine, G. W. Huisman and G. J. Hughes, Science, 2010,
329, 305–309.
33 P. N. Devine, R. M. Howard, R. Kumar, M. P. Thompson,
M. D. Truppo and N. J. Turner, Nat. Rev. Chem., 2018, 2,
409–421.
34 B. J. Wittmann, A. M. Knight, J. Hofstra, S. E. Reisman,
S. B. J. Kan and F. H. Arnold, ACS Catal., 2020, 10(13),
7112–7116.
35 J. Y. L. Chung, B. Marcune, H. R. Strotman, R. I. Petrova,
J. C. Moore and P. G. Dormer, Org. Process Res. Dev., 2015,
19, 1418–1423.This journal is © The Royal Society of Chemistry 202036 I. V. Tetko, J. Gasteiger, R. Todeschini, A. Mauri,
D. Livingstone, P. Ertl, V. A. Palyulin, E. V. Radchenko,
N. S. Zerov, A. S. Makarenko, V. Y. Tanchuk and
V. V. Prokopenko, J. Comput.-Aided Mol. Des., 2005, 19,
453–463.
37 I. Colomer, C. J. Empson, P. Craven, Z. Owen, R. G. Doveston,
I. Churcher, S. P. Marsden and A. Nelson, Chem. Commun.,
2016, 52, 7209–7212.
38 W. H. B. Sauer and M. K. Schwarz, J. Chem. Inf. Comput. Sci.,
2003, 43, 987–1003.
39 N. J. Turner and E. O'Reilly, Nat. Chem. Biol., 2013, 9, 285–
288.
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